Get the latest news, insights, and market updates on OKYO (OKYO Pharma Limited). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO), highlighting the company’s promising urcosimod program and its potential to address an unmet need in neuropathic corneal pain (NCP). The positive sentiment... Feb 17, 2026 - $OKYO
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage biopharmaceutical company said it intends to use the net proceeds primarily to fund the... Feb 13, 2026 - $OKYO
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an addit Feb 13, 2026 - $OKYO
OKYO Pharma Announces Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option t Feb 12, 2026 - $OKYO
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners. Leerink Partners will replace B.... Feb 11, 2026 - $OKYO
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities I Feb 11, 2026 - $OKYO
OKYO Pharma appoints Flavio Mantelli as chief medical officer
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, has appointed Flavio Mantelli as its Chief Medical Officer. Dr Mantelli joins OKYO Pharma with extensive experience in ocular... Feb 10, 2026 - $OKYO
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Flavio Mantelli, MD, PhD, OKYO Pharma Chief Medical Officer Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to Feb 10, 2026 - $OKYO
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The accepted paper, ti Jan 30, 2026 - $OKYO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple